These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 17443608)

  • 1. Cotrimoxazole for prophylaxis or treatment of opportunistic infections of HIV/AIDS in patients with previous history of hypersensitivity to cotrimoxazole.
    Lin D; Li WK; Rieder MJ
    Cochrane Database Syst Rev; 2007 Apr; (2):CD005646. PubMed ID: 17443608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cotrimoxazole prophylaxis for opportunistic infections in adults with HIV.
    Grimwade K; Swingler ; G
    Cochrane Database Syst Rev; 2003; 2003(3):CD003108. PubMed ID: 12917946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cotrimoxazole prophylaxis for opportunistic infections in children with HIV infection.
    Grimwade K; Swingler GH
    Cochrane Database Syst Rev; 2006 Jan; 2006(1):CD003508. PubMed ID: 16437457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cotrimoxazole prophylaxis for opportunistic infections in children with HIV infection.
    Grimwade K; Swingler G
    Cochrane Database Syst Rev; 2003; (2):CD003508. PubMed ID: 12804472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of tuberculosis preventive therapy on tuberculosis and mortality in HIV-infected children.
    Gray DM; Zar H; Cotton M
    Cochrane Database Syst Rev; 2009 Jan; (1):CD006418. PubMed ID: 19160285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients.
    Stern A; Green H; Paul M; Vidal L; Leibovici L
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD005590. PubMed ID: 25269391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of diarrhoea in children with HIV infection or exposure to maternal HIV infection.
    Humphreys EH; Smith NA; Azman H; McLeod D; Rutherford GW
    Cochrane Database Syst Rev; 2010 Jun; (6):CD008563. PubMed ID: 20556793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TNF, LTA, HSPA1L and HLA-DR gene polymorphisms in HIV-positive patients with hypersensitivity to cotrimoxazole.
    Alfirevic A; Vilar FJ; Alsbou M; Jawaid A; Thomson W; Ollier WE; Bowman CE; Delrieu O; Park BK; Pirmohamed M
    Pharmacogenomics; 2009 Apr; 10(4):531-40. PubMed ID: 19374512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of toxoplasmic encephalitis in HIV-infected adults (with an emphasis on resource-poor settings).
    Dedicoat M; Livesley N
    Cochrane Database Syst Rev; 2006 Jul; (3):CD005420. PubMed ID: 16856096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients.
    Green H; Paul M; Vidal L; Leibovici L
    Cochrane Database Syst Rev; 2007 Jul; (3):CD005590. PubMed ID: 17636808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Seven hours for effective and safe desensitization in HIV-positive patients intolerant to cotrimoxazole].
    El Benaye J; Nihal B; Hicham J; Mohamed E
    Pan Afr Med J; 2014; 18():238. PubMed ID: 25426196
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost-effectiveness of cotrimoxazole prophylaxis among persons with HIV in Uganda.
    Pitter C; Kahn JG; Marseille E; Lule JR; McFarland DA; Ekwaru JP; Bunnell R; Coutinho A; Mermin J
    J Acquir Immune Defic Syndr; 2007 Mar; 44(3):336-43. PubMed ID: 17327758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interventions for the treatment of decreased bone mineral density associated with HIV infection.
    Lin D; Rieder MJ
    Cochrane Database Syst Rev; 2007 Apr; (2):CD005645. PubMed ID: 17443607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful desensitization to dapsone for Pneumocystis carinii prophylaxis in an HIV-positive patient.
    Cook DE; Kossey JL
    Ann Pharmacother; 1998 Dec; 32(12):1302-5. PubMed ID: 9876811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trimethoprim-sulfamethoxazole oral desensitization in hemophiliacs infected with human immunodeficiency virus with a history of hypersensitivity reactions.
    Kletzel M; Beck S; Elser J; Shock N; Burks W
    Am J Dis Child; 1991 Dec; 145(12):1428-9. PubMed ID: 1688295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of the impact of cotrimoxazole prophylaxis on key outcomes among HIV-infected adults in low- and middle-income countries: a systematic review.
    Saadani Hassani A; Marston BJ; Kaplan JE
    J Acquir Immune Defic Syndr; 2015 Apr; 68 Suppl 3(Suppl 3):S257-69. PubMed ID: 25768865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, pilot trial comparing full versus escalating dose regimens for the desensitization of AIDS patients allergic to sulfonamides.
    Straatmann A; Bahia F; Pedral-Sampaio D; Brites C
    Braz J Infect Dis; 2002 Dec; 6(6):276-80. PubMed ID: 12585970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sulfa hypersensitivity in patients with HIV infection: onset, treatment, critical review of the literature.
    Ryan C; Madalon M; Wortham DW; Graziano FM
    WMJ; 1998 May; 97(5):23-7. PubMed ID: 9617304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials.
    Green H; Paul M; Vidal L; Leibovici L
    Mayo Clin Proc; 2007 Sep; 82(9):1052-9. PubMed ID: 17803871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility and effectiveness of cotrimoxazole prophylaxis for HIV-1-infected adults attending an HIV/AIDS clinic in Uganda.
    Watera C; Todd J; Muwonge R; Whitworth J; Nakiyingi-Miiro J; Brink A; Miiro G; Antvelink L; Kamali A; French N; Mermin J
    J Acquir Immune Defic Syndr; 2006 Jul; 42(3):373-8. PubMed ID: 16810124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.